Although there were no significant differences between the two drugs, alectinib ranked higher than brigatinib in the overall ALK-p, ALK-inhibitor-naïve NSCLC patient population (with and without CNS metastasis), whereas brigatinib ranked higher than alectinib in the CNS metastasis sub-group. The gene discussed is ALK; the disease is non-small cell lung carcinoma.